Abstract
Damage of articular cartilage is a frequent clinical problem and is commonly considered to be irreversible. Fullthickness defects may lead to the formation of fibrous repair tissue of minor mechanical quality, while partial-thickness lesions hardly show any repair response. Surgical approaches often fail to restore the articular surface, facing the problem of incomplete chondrogenesis or rapid degradation of the repair tissue. However, advances in molecular biology have revealed the potential of growth factors, differentiation factors, and cytokines in directing cellular differentiation and metabolic activity. Anabolic factors including members of the TGF-ß superfamily, IGF-1, FGF, or HGF have proven their potential to stimulate chondrogenesis and synthesis of cartilage-specific matrix components, allowing the formation of a hyaline cartilage-like repair tissue in experimental studies. In addition, anti-catabolic or anti-inflammatory molecules, such as IL-4, IL-10, IL-1Ra, and TNFsR may also exert beneficial effects by inhibiting excessive cartilage degradation. Although it is questionable whether regeneration of hyaline cartilage implying a complete restoration of the articular surface by a tissue that is identical with the original can ever be achieved, all these molecules have been considered as suitable tools for cartilage repair. The transfer of the respective genes into the joint, possibly in combination with the supply of chondroprogenitor cells, might be an elegant method to achieve a sustained delivery of such therapeutic factors at the required location in vivo. This review focuses on the therapeutic molecules, the suitability of different viral and nonviral vectors for intraarticular gene transfer and the lessons learned from gene therapy studies on various animal models.
Keywords: hyaline cartilage, tissue engineering, gene therapy, growth factor, osteoarthritis, sports injury, chondrogenesis
Current Gene Therapy
Title: Cartilage Regeneration by Gene Therapy
Volume: 3 Issue: 4
Author(s): K. Gelse, K. von der Mark and H. Schneider
Affiliation:
Keywords: hyaline cartilage, tissue engineering, gene therapy, growth factor, osteoarthritis, sports injury, chondrogenesis
Abstract: Damage of articular cartilage is a frequent clinical problem and is commonly considered to be irreversible. Fullthickness defects may lead to the formation of fibrous repair tissue of minor mechanical quality, while partial-thickness lesions hardly show any repair response. Surgical approaches often fail to restore the articular surface, facing the problem of incomplete chondrogenesis or rapid degradation of the repair tissue. However, advances in molecular biology have revealed the potential of growth factors, differentiation factors, and cytokines in directing cellular differentiation and metabolic activity. Anabolic factors including members of the TGF-ß superfamily, IGF-1, FGF, or HGF have proven their potential to stimulate chondrogenesis and synthesis of cartilage-specific matrix components, allowing the formation of a hyaline cartilage-like repair tissue in experimental studies. In addition, anti-catabolic or anti-inflammatory molecules, such as IL-4, IL-10, IL-1Ra, and TNFsR may also exert beneficial effects by inhibiting excessive cartilage degradation. Although it is questionable whether regeneration of hyaline cartilage implying a complete restoration of the articular surface by a tissue that is identical with the original can ever be achieved, all these molecules have been considered as suitable tools for cartilage repair. The transfer of the respective genes into the joint, possibly in combination with the supply of chondroprogenitor cells, might be an elegant method to achieve a sustained delivery of such therapeutic factors at the required location in vivo. This review focuses on the therapeutic molecules, the suitability of different viral and nonviral vectors for intraarticular gene transfer and the lessons learned from gene therapy studies on various animal models.
Export Options
About this article
Cite this article as:
Gelse K., Mark von der K. and Schneider H., Cartilage Regeneration by Gene Therapy, Current Gene Therapy 2003; 3 (4) . https://dx.doi.org/10.2174/1566523034578276
DOI https://dx.doi.org/10.2174/1566523034578276 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemoresistance in Non-Small Cell Lung Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia?
Current Pharmaceutical Design Recent Progress on the Discovery of NLRP3 Inhibitors and their Therapeutic Potential
Current Medicinal Chemistry Nutrigenomics and Its Approaches for Control of Chronic Diseases
Current Biotechnology Hepatitis B Vaccination in HIV-Infected Subjects
Current Molecular Pharmacology Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry Adipobiology of Disease: Adipokines and Adipokine-Targeted Pharmacology
Current Pharmaceutical Design PARG Inhibitors and Functional PARG Inhibition Models
Current Protein & Peptide Science Treating Chronic Hepatitis B: Today and Tomorrow
Current Medicinal Chemistry Aminoacid Support in the Prevention of Diabetes and Diabetic Complications
Current Protein & Peptide Science Cytochrome P450 in Neurological Disease
Current Drug Metabolism New Drug Targets for Hepatitis C and Other Flaviviridae Viruses
Infectious Disorders - Drug Targets Ascorbic Acid in Postoperative Intensive Care Patients - Biochemical Aspects and Clinical Experience
Current Medicinal Chemistry Targeting HIV-1 gp41 in Close Proximity to the Membrane Using Antibody and Other Molecules
Current Topics in Medicinal Chemistry The Janus Face of Adenosine: Antiarrhythmic and Proarrhythmic Actions
Current Pharmaceutical Design Nitric Oxide: A Key Mediator of Biofilm Dispersal with Applications in Infectious Diseases
Current Pharmaceutical Design Multidisciplinary Cancer Therapy with Telomerase-Specific Oncolytic Adenovirus
Current Cancer Therapy Reviews Current Anti-Inflammatory Therapies and the Potential of Secretory Phospholipase A2 Inhibitors in the Design of New Anti-Inflammatory Drugs: A Review of 2012 - 2018
Current Medicinal Chemistry γ-Secretase Modulation and its Promise for Alzheimers Disease: a Medicinal Chemistry Perspective
Current Topics in Medicinal Chemistry Searching for Predictive Blood Biomarkers: Misfolded p53 In Mild Cognitive Impairment
Current Alzheimer Research